北京若生智能科技有限公司
Drug Database
DO

donepezil (E 2022 / TK023 / TK 023)

✓ Approved

Eisai Co., Ltd. · ACHE · 小分子

什么是 donepezil？

donepezil 是一种小分子，由Eisai Co., Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Transdermal。

药物档案

商品名E 2022, TK023, TK 023
公司Eisai Co., Ltd.
药物类别小分子
分子靶点ACHE
给药途径Transdermal
状态Approved
来源： ClinicalTrials.gov, Eisai Co., Ltd.

作用机制

分子靶点

donepezil 作用于 1 个分子靶点：

ACHEacetylcholinesterase (Cartwright blood group) (N-ACHE, ACEE)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

donepezil 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDementia Alzheimer's typePhase I

相关研究文献

PubMedAnnals of thoracic surgery short reports2026-09-10

Early Biological Reaction to a Synthetic Hybrid Patch Inducing Tissue Ingrowth as a Senning Atrial Baffle.

Yamaguchi Akira A, Murayama Hiroomi H, Nemoto Shintaro S

We report a case in which a new synthetic hybrid patch inducing autologous tissue ingrowth was used to replace the obstructed Senning atrial baffle in a double switch operation for congenitally corrected transposition of the great arteries. However, recurrent baffle obstruction developed after 10 months postoperatively and was removed. Histology of the excised specimen showed promising tissue ingrowth but cautionary peripheral folding of the patch in this clinically challenging condition.

PMID 42719605
阅读全文 →
PubMedChemical record (New York, N.Y.)2026-09-10

From Barrier Disruption to Precision Skin Interface Engineering: Next-Generation Transdermal Drug Delivery.

Zhou Cong-Zheng CZ, Lin Xin-Yu XY, Yu Shou-Shan SS, Qiao Sheng-Lin SL

Transdermal drug delivery (TDD) is reemerging as a clinically attractive route for noninvasive therapy, driven by the growing demand for alternatives to repeated injection and by the rapid development of materials capable of regulating transport across the skin. By avoiding gastrointestinal degradation and hepatic first-pass metabolism, TDD can provide prolonged drug exposure, reduce peak-to-trough fluctuations in plasma concentration, and improve adherence in long-term treatment. Its broader implementation, however, is still constrained by the exceptional barrier function of the stratum corneum, which severely limits the passive transport of hydrophilic molecules, charged species, and macromolecular therapeutics. In this review, we critically discuss the structural basis of the skin barrier and summarize the evolution of TDD strategies from conventional chemical permeation enhancement and device-assisted physical disruption to nanocarrier-mediated, biomimetic, and intelligent bio-delivery systems. Particular emphasis is placed on the mechanistic logic that connects carrier composition, interfacial interactions, skin microenvironment remodeling, and therapeutic performance. Representative examples are analyzed to highlight both opportunities and translational bottlenecks. Finally, we outline future directions in multimodal delivery, pathology-adapted design, standardized evaluation, and scalable manufacturing, which will be essential for transforming TDD from a permeability enhancement technology into a precision-regulated therapeutic platform.

PMID 42717625
阅读全文 →
PubMedClinical medicine insights. Endocrinology and diabetes2026-09-10

Efficacy and Safety of an Insulin Patch Pump Compared to Multiple Daily Injections in Pediatric Patients With Diabetes: A Randomized, Open-Label, Crossover, Non-Inferiority Clinical Trial.

Fu Junfen J, Wu Jin J, Hui Yao Y, Zhu Weiwei W et al.

Insulin patch pumps offer advantages over multiple daily injections (MDI) for pediatric diabetes, but randomized trial evidence in Chinese children remains limited. To evaluate the efficacy and safety of a tubeless insulin patch pump (Equil™) compared with MDI in children and adolescents with diabetes. This multicenter, open-label, randomized, crossover, non-inferiority trial was conducted at seven pediatric endocrinology centers in China (September 2021 - October 2022). Patients aged 3-17 years with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) were randomized 1:1 to receive continuous subcutaneous insulin infusion (CSII) via Equil™ or MDI via insulin pen for 5 days, followed by crossover. The primary outcome was mean blood glucose (MBG). Non-inferiority margin was pre-specified as 0.386 mmol/L. Secondary outcomes included glycemic variability (standard deviation of blood glucose, SDBG), glycated albumin (GA), total daily insulin dose (TDD), hypoglycemia frequency, and adverse events. Patient satisfaction was assessed using a study-specific 11-item questionnaire. Of 74 enrolled patients, 72 (97.3%) completed the study. CSII demonstrated non-inferiority to MDI for MBG (8.43±1.88 mmol/L, n=74, vs 9.00±2.04 mmol/L, n=72); mean difference -0.606 mmol/L; 95% CI -0.988 to -0.223; upper CI limit -0.223 < non-inferiority margin 0.386. No significant differences were observed for secondary outcomes (SDBG: 3.019 vs 3.357; GA change: 2.52±3.03% vs 2.02±3.25%, p=0.184; TDD: 132.17±78.43 vs 147.52±91.59 IU, p=0.159; hypoglycemia events: 114 vs 106). Adverse event rates were similar (75.7% vs 69.4%, p=0.399); no serious adverse events occurred. Patient satisfaction was significantly higher with CSII (total score 21.03±4.47 vs 22.00±3.99; mean difference -0.97, 95% CI -1.75 to -0.19; p=0.015), with 68.1% of patients preferring the patch pump. The Equil™ patch pump is non-inferior to MDI in terms of glycemic control and safety for pediatric diabetes patients, with higher patient satisfaction. These findings support the patch pump as an effective alternative for children and adolescents requiring exogenous insulin therapy.

PMID 42719483
阅读全文 →
PubMedNature communications2026-09-10

Multiple-layer mesh from electrospinnable amyloid‑like protein and their application in treating oral ulcer.

Tian Juanhua J, Zhang Yujia Y, Li Yan Y, Liu Yongchun Y et al.

Oral ulcers significantly impair quality of life due to prolonged severe pain caused by delayed healing. The moist, dynamic, microorganism‑rich environment hinders natural scab formation and ordinary patch adhesion, limiting therapeutic outcomes. Inspired by bioadhesion, we propose an unfolding‑stabilization strategy to overcome globular protein electrospinning limitations and construct a multifunctional patch. Water triggers a conformational transition to an amyloid‑like β‑sheet interface that disrupts the hydration layer for initial wet adhesion, while Carbomer-mucin interactions further enhance retention. This synergy gives adhesion strength 6-50 times that of commercial products, enabling sustained attachment in complex oral environments for effective ulcer protection. Glycyrrhetinic acid provides local antibacterial and anti‑inflammatory effects. In a rat model, the patch improves healing by 75% over the best commercial control. It also matches the mucosal modulus, while being steroid‑free, biodegradable, and biocompatible. By integrating electrospinning with amyloid‑mediated adhesion, this work offers a scalable strategy for engineering multifunctional wet biointerfaces.

PMID 42716940
阅读全文 →
PubMedThe international journal of medical robotics + computer assisted surgery : MRCAS2026-09-10

Entry Point Localisation for Percutaneous Surgical Robots Based on Concentric Fiducial Patches and Robust Surface Fitting.

Deng Youming Y, Jiang Qi Q, Wang Jie J, Tang Jiawei J

Accurate entry point localisation is critical for the safety of robot-assisted percutaneous interventions (RAPI). However, medical optical tracking systems for the traditional fiducial patch are cost-prohibitive. To address these challenges, this paper proposes a robust entry point and gesture localisation framework based on an inexpensive concentric fiducial patch and robust surface fitting. We introduce an anisotropic iteratively reweighted least squares (IRLS) algorithm integrated with a Tukey biweight M-estimator, employing a deterministic soft-weighting strategy to effectively suppress gross outliers and smooth out high-frequency sensor noise. Experimental results demonstrate that the proposed method has high accuracy and robustness, achieving an MAE of 1.47 mm in dynamic respiratory tracking and maintains stable detection even under 60% occlusion and low-light conditions. The results suggest that this framework provides a reliable and low-cost solution for surgical navigation in unstructured clinical environments.

PMID 42717850
阅读全文 →
PubMedAnnals of thoracic surgery short reports2026-09-10

Bicuspidization of the Unicuspid Aortic Valve: Neocommissure Reconstruction Preserving the Native Free Margin.

Kawabata Ryo R, Tsunemi Kotaro K, Oka Takanori T, Okita Yutaka Y

This report presents a bicuspidization technique for unicuspid aortic valve repair. To enhance long-term durability, the native free margin was preserved, and a portion was used to construct a new commissure, thereby minimizing the use of the patch in regions subjected to high mechanical stress. At 6.5 years postoperatively, the valve function remains excellent.

PMID 42719636
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多donepezil